December decision for resubmitted Pozen NDA
This article was originally published in Scrip
Less than three months after the US FDA rejected Pozen's new drug application (NDA) for the preventative cardiovascular drugs PA8140 and PA32540, the agency accepted the company's resubmitted NDA for review and set a year-end decision date for the application.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.